CoChat

The Dual RAF/MEK Inhibitor CH5126766/RO5126766 May Be a Potential Therapy for RAS-Mutated Tumor Cells

Open access

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Abstract

Although melanoma is the most aggressive skin cancer, recent advances in BRAF and/or MEK inhibitors against BRAF-mutated melanoma have improved survival rates. Despite these advances, a treatment strategy targeting NRAS-mutated melanoma has not yet been elucidated. We discovered CH5126766/RO5126766 as a potent and selective dual RAF/MEK inhibitor currently under early clinical trials. We examined the activity of CH5126766/RO5126766 in a panel of malignant tumor cell lines including melanoma with a BRAF or NRAS mutation. Eight cell lines including melanoma were assessed for their sensitivity to the BRAF, MEK, or RAF/MEK inhibitor using in vitro growth assays. CH5126766/RO5126766 induced G1 cell cycle arrest in two melanoma cell lines with the BRAF V600E or NRAS mutation. In these cells, the G1 cell cycle arrest was accompanied by up-regulation of the cyclin-dependent kinase inhibitor p27 and down-regulation of cyclinD1. CH5126766/RO5126766 was more effective at reducing colony formation than a MEK inhibitor in NRAS- or KRAS-mutated cells. In the RAS-mutated cells, CH5126766/RO5126766 suppressed the MEK reactivation caused by a MEK inhibitor. In addition, CH5126766/RO5126766 suppressed the tumor growth in SK-MEL-2 xenograft model. The present study indicates that CH5126766/RO5126766 is an attractive RAF/MEK inhibitor in RAS-mutated malignant tumor cells including melanoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0113217

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Effects of the RAF/MEK inhibitor CH5126766 and the MEK inhibitor PD0325901 on melanoma cell lines. A, SK-MEL-28 and SK-MEL-2 cells were treated with CH5126766 or PD0325901 at the various concentrations, and cell numbers were determined using a Guava EasyCyte plus flow cytometer. Data represent the means of triplicate with SD indicated. Significance was assessed by a Student's t test. *, P<0.05; **, P<0.01 significantly different from DMSO-treated controls. B, SK-MEL-28 and SK-MEL-2 cells were treated with the indicated concentrations of CH5126766 or PD0325901 for 24 h. The percentage of cells in each phase of the cell cycle was determined by flow cytometry. Data represent means of triplicate with SD indicated. Statistical significance was assessed by a Student's t test. *, P<0.05; **, P<0.01 compared with DMSO-treated controls. C, Representative histogram patterns from SK-MEL-28 and SK-MEL-2 cells. D, SK-MEL-28 and SK-MEL-2 cells were treated with the indicated concentrations of CH5126766 or PD0325901 for 24 h, and cell extracts were analysed by immunoblotting. E, Clonogenic suppression by CH5126766 and PD0325901 in melanoma cells. SK-MEL-28 and SK-MEL-2 cells were treated for 72 h with 10 nM of PD0325901 or 100 nM of CH5126766. After 14 days, colony numbers were counted. Data represent the means of triplicate with SD indicated. Significance was assessed by a Student's t test. **, P<0.01. CH; CH5126766, PD; PD0325901
Figure 1 Effects of the RAF/MEK inhibitor CH5126766 and the MEK inhibitor PD0325901 on melanoma cell lines. A, SK-MEL-28 and SK-MEL-2 cells were treated with CH5126766 or PD0325901 at the various concentrations, and cell numbers were determined using a Guava EasyCyte plus flow cytometer. Data represent the means of triplicate with SD indicated. Significance was assessed by a Student's t test. *, P<0.05; **, P<0.01 significantly different from DMSO-treated controls. B, SK-MEL-28 and SK-MEL-2 cells were treated with the indicated concentrations of CH5126766 or PD0325901 for 24 h. The percentage of cells in each phase of the cell cycle was determined by flow cytometry. Data represent means of triplicate with SD indicated. Statistical significance was assessed by a Student's t test. *, P<0.05; **, P<0.01 compared with DMSO-treated controls. C, Representative histogram patterns from SK-MEL-28 and SK-MEL-2 cells. D, SK-MEL-28 and SK-MEL-2 cells were treated with the indicated concentrations of CH5126766 or PD0325901 for 24 h, and cell extracts were analysed by immunoblotting. E, Clonogenic suppression by CH5126766 and PD0325901 in melanoma cells. SK-MEL-28 and SK-MEL-2 cells were treated for 72 h with 10 nM of PD0325901 or 100 nM of CH5126766. After 14 days, colony numbers were counted. Data represent the means of triplicate with SD indicated. Significance was assessed by a Student's t test. **, P<0.01. CH; CH5126766, PD; PD0325901CC BY · PubMed Central
Figure 2 The RAF inhibitor PLX4720 negated MEK inhibition by PD0325901 in a NRAS-mutated cell line. A, SK-MEL-2 cells were treated with PLX4720 in the presence or absence of CH5126766 or PD0325901 for 24 h. Cell extracts were analysed by immunoblotting for the indicated proteins. B, Clonogenic suppression by PD0325901 and/or PLX4720 in NRAS-mutated SK-MEL-2 cells. SK-MEL-2 cells were treated for 72 h with 100 nM of CH5126766, or 10 nM of PD0325901 in the presence or absence of 1 µM of PLX4720. After 14 days, colony numbers were counted. Data represent the means of triplicate with SD indicated. Significance was assessed by a Student's t test. *, P<0.05; **, P<0.01. CH; CH5126766, PD; PD0325901, PLX; PLX4720
Figure 2 The RAF inhibitor PLX4720 negated MEK inhibition by PD0325901 in a NRAS-mutated cell line. A, SK-MEL-2 cells were treated with PLX4720 in the presence or absence of CH5126766 or PD0325901 for 24 h. Cell extracts were analysed by immunoblotting for the indicated proteins. B, Clonogenic suppression by PD0325901 and/or PLX4720 in NRAS-mutated SK-MEL-2 cells. SK-MEL-2 cells were treated for 72 h with 100 nM of CH5126766, or 10 nM of PD0325901 in the presence or absence of 1 µM of PLX4720. After 14 days, colony numbers were counted. Data represent the means of triplicate with SD indicated. Significance was assessed by a Student's t test. *, P<0.05; **, P<0.01. CH; CH5126766, PD; PD0325901, PLX; PLX4720CC BY · PubMed Central
Figure 3 Effects of the RAF/MEK inhibitor CH5126766 and the MEK inhibitor PD0325901 on KRAS-mutated cell lines. A, MIAPaCa-2 and SW480 cells were treated with CH5126766 or PD0325901 at the indicated concentrations for 24 h, and cell extracts were analysed by immunoblotting for the indicated proteins. B, Clonogenic suppression by CH5126766 or PD0325901 in MIAPaCa-2 cells. MIAPaCa-2 cells were treated for 72 h with 40 nM of CH5126766 or 1.5 nM of PD0325901. After 14 days, colony numbers were counted. Data represent the means of triplicate with SD indicated. Significance was assessed by a Student's t test. **, P<0.01. C, MIAPaCa-2 cells were treated with CH5126766 or PD0325901 in the presence or absence of PLX4720 at the indicated concentrations for 24 h, and cell extracts were analysed by immunoblotting for the indicated proteins. D, Clonogenic suppression by PD0325901 and/or PLX4720 in MIAPaCa-2 cells. MIAPaCa-2 cells were treated for 72 h with 40 nM of CH5126766, or 1.5 nM of PD0325901 in the presence or absence of 1 µM of PLX4720. After 14 days, colony numbers were counted. Data represent the means of triplicate with SD indicated. Significance was assessed by a Student's t test. *, P<0.05; **, P<0.01. CH; CH5126766, PD; PD0325901, PLX; PLX4720
Figure 3 Effects of the RAF/MEK inhibitor CH5126766 and the MEK inhibitor PD0325901 on KRAS-mutated cell lines. A, MIAPaCa-2 and SW480 cells were treated with CH5126766 or PD0325901 at the indicated concentrations for 24 h, and cell extracts were analysed by immunoblotting for the indicated proteins. B, Clonogenic suppression by CH5126766 or PD0325901 in MIAPaCa-2 cells. MIAPaCa-2 cells were treated for 72 h with 40 nM of CH5126766 or 1.5 nM of PD0325901. After 14 days, colony numbers were counted. Data represent the means of triplicate with SD indicated. Significance was assessed by a Student's t test. **, P<0.01. C, MIAPaCa-2 cells were treated with CH5126766 or PD0325901 in the presence or absence of PLX4720 at the indicated concentrations for 24 h, and cell extracts were analysed by immunoblotting for the indicated proteins. D, Clonogenic suppression by PD0325901 and/or PLX4720 in MIAPaCa-2 cells. MIAPaCa-2 cells were treated for 72 h with 40 nM of CH5126766, or 1.5 nM of PD0325901 in the presence or absence of 1 µM of PLX4720. After 14 days, colony numbers were counted. Data represent the means of triplicate with SD indicated. Significance was assessed by a Student's t test. *, P<0.05; **, P<0.01. CH; CH5126766, PD; PD0325901, PLX; PLX4720CC BY · PubMed Central
Figure 4 Oncogenic NRAS required CRAF to activate the MEK/ERK pathway. A, SK-MEL-2 cells were transfected with siRNAs for the negative control (N), BRAF (B), or CRAF (C), and without siRNAs for mock (M). After the indicated times, cell extracts were analysed by immunoblotting for the indicated proteins. B, SK-MEL-2 cells were transfected with siRNA for the negative control (N), BRAF (B), and CRAF (C) , and without siRNAs for mock (M). After 24 h, 100 nM of CH5126766 or 10 nM of PD0325901 were added to the cells. The cells were harvested for immunoblot analysis after 24 h. CH; CH5126766, PD; PD0325901
Figure 4 Oncogenic NRAS required CRAF to activate the MEK/ERK pathway. A, SK-MEL-2 cells were transfected with siRNAs for the negative control (N), BRAF (B), or CRAF (C), and without siRNAs for mock (M). After the indicated times, cell extracts were analysed by immunoblotting for the indicated proteins. B, SK-MEL-2 cells were transfected with siRNA for the negative control (N), BRAF (B), and CRAF (C) , and without siRNAs for mock (M). After 24 h, 100 nM of CH5126766 or 10 nM of PD0325901 were added to the cells. The cells were harvested for immunoblot analysis after 24 h. CH; CH5126766, PD; PD0325901CC BY · PubMed Central
Figure 5 Antitumor activity of CH5126766 in a xenograft model of SK-MEL-2 cells. No animals died or had more than 10% of their body weight gain or loss from baseline in these experiments. Vehicle or CH5126766 was administered orally every day for eleven days. Statistical analysis was conducted by using Dunnett test. *, P<0.05. ▾; Administration of vehicle or CH5126766
Figure 5 Antitumor activity of CH5126766 in a xenograft model of SK-MEL-2 cells. No animals died or had more than 10% of their body weight gain or loss from baseline in these experiments. Vehicle or CH5126766 was administered orally every day for eleven days. Statistical analysis was conducted by using Dunnett test. *, P<0.05. ▾; Administration of vehicle or CH5126766CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 44 references

Cited by

See all 50

Metadata

Authors
Wada, M., Horinaka, M., Yamazaki, T., Katoh, N., & Sakai, T.
Affiliations
  • Kyoto Prefectural University of Medicine (JP)
  • Chugai Pharmaceutical Co., Ltd. (Japan) (JP)
Corresponding author
Sakai, Toshiyuki
Venue
PLoS ONE
Published
2014-11-25
Volume
9
Issue
11
Pages
e113217
ISSN
1932-6203 (ISSN-L)
OpenAlex
W1973794173
Cited by
50
References
44
Citations by year
2026: 1 · 2025: 2 · 2024: 3 · 2023: 3 · 2022: 6 · 2021: 9 · 2020: 4 · 2019: 5 · 2018: 7 · 2017: 3 · 2016: 4 · 2015: 3
FWCI
1.37
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Chugai Pharmaceutical
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
RAS mutations, NRAS-mutated melanoma, BRAF V600E mutation, G1 cell cycle arrest, p27, cyclin D1, KRAS mutation, tumor growth inhibition, melanoma cell lines
MeSH terms
Animals, Coumarins, Humans, Mutation, Neoplasms, Genes, ras, MAP Kinase Kinase Kinases, Xenograft Model Antitumor Assays, Cell Line, Tumor, Protein Kinase Inhibitors, raf Kinases, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Dual RAF/MEK Inhibitor CH5126766/RO5126766 May Be a Potential Therapy for RAS-Mutated Tumor Cells. https://app.cochat.ai/papers/10.1371/journal.pone.0113217
The paper
Wada, M., Horinaka, M., Yamazaki, T., Katoh, N., & Sakai, T. (2014). The Dual RAF/MEK Inhibitor CH5126766/RO5126766 May Be a Potential Therapy for RAS-Mutated Tumor Cells. PLoS ONE. https://doi.org/10.1371/journal.pone.0113217

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.